Versor Investments LP Invests $102,000 in Evolus, Inc. $EOLS

Versor Investments LP purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 2nd quarter, Holdings Channel reports. The fund purchased 11,049 shares of the company’s stock, valued at approximately $102,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Evolus during the 1st quarter worth about $12,330,000. Pinnacle Associates Ltd. acquired a new stake in shares of Evolus during the 2nd quarter worth approximately $6,318,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Evolus during the first quarter worth approximately $5,851,000. Panagora Asset Management Inc. acquired a new position in Evolus in the first quarter valued at approximately $2,937,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in Evolus by 594.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 259,487 shares of the company’s stock valued at $2,390,000 after buying an additional 222,126 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Stock Performance

Shares of EOLS opened at $6.56 on Friday. The firm has a market capitalization of $425.22 million, a PE ratio of -7.13 and a beta of 0.97. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.12. The stock has a 50 day simple moving average of $6.67 and a 200 day simple moving average of $8.37.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $18.00 target price on shares of Evolus in a report on Monday, September 8th. HC Wainwright reduced their price target on Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a report on Saturday. Needham & Company LLC restated a “hold” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, August 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $21.25.

Insider Buying and Selling at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the transaction, the chief marketing officer directly owned 89,949 shares of the company’s stock, valued at approximately $675,516.99. This represents a 5.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady Stewart bought 30,000 shares of the stock in a transaction on Friday, August 15th. The shares were purchased at an average price of $6.82 per share, with a total value of $204,600.00. Following the acquisition, the director owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 5.90% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.